BURLINGTON, Mass. , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
BURLINGTON, Mass. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference . The virtual
AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of
Initial findings from proof-of-concept trial in patients undergoing bunionectomy support expansion of the study to include 36 additional patients Data from the trial, including the expansion cohort, anticipated by year-end BURLINGTON, Mass. , Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics,
Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data indicate the total and maximal exposure to triamcinolone acetonide (TA) was approximately two-thirds lower in
ZILRETTA® ( triamcinolone acetonide extended-release injectable suspension) net sales were $28 .2 million in Q2 2021, reflecting growth of 15% over the previous quarter Net loss in Q2 2021 decreased by $10 .4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on
BURLINGTON, Mass. , July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET .
BURLINGTON, Mass. , July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar , Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion’s audit committee.
